Form 8-K

8-K — ENANTA PHARMACEUTICALS INC

Accession: 0001193125-26-274950

Filed: 2026-06-18

Period: 2026-06-18

CIK: 0001177648

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — d159604d8k.htm (Primary)

EX-99.1 (d159604dex991.htm)

EX-99.2 (d159604dex992.htm)

GRAPHIC (g159604ex99_2p10g1.jpg)

GRAPHIC (g159604ex99_2p11g1.jpg)

GRAPHIC (g159604ex99_2p12g1.jpg)

GRAPHIC (g159604ex99_2p13g1.jpg)

GRAPHIC (g159604ex99_2p14g1.jpg)

GRAPHIC (g159604ex99_2p15g1.jpg)

GRAPHIC (g159604ex99_2p16g1.jpg)

GRAPHIC (g159604ex99_2p17g1.jpg)

GRAPHIC (g159604ex99_2p18g1.jpg)

GRAPHIC (g159604ex99_2p19g1.jpg)

GRAPHIC (g159604ex99_2p1g1.jpg)

GRAPHIC (g159604ex99_2p20g1.jpg)

GRAPHIC (g159604ex99_2p21g1.jpg)

GRAPHIC (g159604ex99_2p22g1.jpg)

GRAPHIC (g159604ex99_2p23g1.jpg)

GRAPHIC (g159604ex99_2p24g1.jpg)

GRAPHIC (g159604ex99_2p25g1.jpg)

GRAPHIC (g159604ex99_2p26g1.jpg)

GRAPHIC (g159604ex99_2p27g1.jpg)

GRAPHIC (g159604ex99_2p28g1.jpg)

GRAPHIC (g159604ex99_2p29g1.jpg)

GRAPHIC (g159604ex99_2p2g1.jpg)

GRAPHIC (g159604ex99_2p3g1.jpg)

GRAPHIC (g159604ex99_2p4g1.jpg)

GRAPHIC (g159604ex99_2p5g1.jpg)

GRAPHIC (g159604ex99_2p6g1.jpg)

GRAPHIC (g159604ex99_2p7g1.jpg)

GRAPHIC (g159604ex99_2p8g1.jpg)

GRAPHIC (g159604ex99_2p9g1.jpg)

GRAPHIC (g159604g0609081059318.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d159604d8k.htm · Sequence: 1

8-K

ENANTA PHARMACEUTICALS INC false 0001177648 0001177648 2026-06-18 2026-06-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2026

ENANTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-35839

04-3205099

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

4 Kingsbury Avenue

Watertown, Massachusetts

02472

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 607-0800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.01 per share

ENTA

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

On June 18, 2026, Enanta Pharmaceuticals, Inc. (“Enanta” or the “Company”) issued a press release announcing the advancement of its zelicapavir clinical development program for the treatment of respiratory syncytial virus (“RSV”), including plans for a registrational Phase 2b/3 clinical trial in high-risk adults and a Phase 2b clinical trial in pediatric patients. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by this reference. In connection with this announcement, the Company also compiled a presentation entitled “Zelicapavir Update” (the “Presentation”) that provides an overview of its RSV program and development plans. A copy of the Presentation is furnished as Exhibit 99.2 hereto and is incorporated herein by this reference.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Exhibit Description

99.1

Press release dated June 18, 2026

99.2

Slide presentation entitled “Zelicapavir Update”

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 18, 2026

ENANTA PHARMACEUTICALS, INC.

By:

/s/ Jay R. Luly, Ph.D.

Jay R. Luly, Ph.D.

President and Chief Executive Officer

EX-99.1

Filename: d159604dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the

Treatment of Respiratory Syncytial Virus (RSV)

•

Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline

Phase 2b Data Expected in 2027

•

Phase 2b Trial of Zelicapavir to Initiate in Pediatric Patients with RSV in 3Q 2026, with Topline Data

Expected in 2027

WATERTOWN, Mass., June 18, 2026 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage

biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced it is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes

from RSV infection after a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The Phase 2b portion of the trial will confirm the

treatment effect with topline data expected in 2027. Enanta also announced plans to initiate a Phase 2b clinical trial of zelicapavir in pediatric patients with RSV, with topline data expected in 2027.

“We are thrilled to move zelicapavir into a single Phase 2b/3 registrational clinical trial in adults with RSV at high risk of progressing to severe

disease, following a productive and collaborative End-of-Phase 2 meeting with the FDA. This progress, alongside the planned initiation of our pediatric Phase 2b trial,

provides the opportunity for two key Phase 2b datasets next year in two important patient populations and underscores zelicapavir’s potential to become the first antiviral therapy for RSV infection,” said Jay R. Luly, Ph.D., President

and Chief Executive Officer of Enanta Pharmaceuticals. “RSV results in a substantial global disease burden, with no available treatment options. We estimate an oral RSV antiviral for children and all high-risk adults represents a global market

opportunity of over $2 billion, with a potential total addressable population of greater than 3 million patients in the United States alone. The recent availability of at-home RSV diagnostics is

expected to further drive disease awareness and increase earlier diagnosis. As we advance into late-stage development, we are well-positioned to continue our leadership in RSV and remain urgently focused on delivering zelicapavir to patients in need

of treatment.”

“We now have a clear and efficient pathway to advance zelicapavir into a registrational program through a single Phase 2b/3

trial. The Phase 2b part is designed to confirm the primary endpoint and treatment effect size in the targeted population and will provide a key dataset to further strengthen the body of evidence supporting the Phase 3 portion of the study. We look

forward to beginning the trial in the fourth quarter of 2026, with data from the Phase 2b portion expected in 2027,” said Scott T. Rottinghaus, M.D., Chief Medical Officer of Enanta Pharmaceuticals. “We are also excited to advance

zelicapavir development in children, with a Phase 2b trial to be conducted in collaboration with the Penta Foundation, a leading organization dedicated to pediatric infectious disease research, and the internationally recognized AMS-PHPT Research Unit at Chiang Mai University. This trial will build on the encouraging findings from our first-in-pediatrics study

and allow us to assess zelicapavir’s treatment effect on symptom resolution using RESOLVE-P, our proprietary tool being developed for use as a registrational endpoint. We plan to initiate this pediatric

study in the third quarter of 2026, with topline data expected in 2027.”

Adult Registration Study

The Phase 2b/3 randomized, double-blind, placebo-controlled, multicenter global trial will evaluate the efficacy and safety of zelicapavir in adult outpatients

who test positive for RSV and have had respiratory tract infection symptoms for no more than 3 days. Patients will have at least one of the following risk factors: 75 years of age or older, chronic obstructive pulmonary disease (COPD), or congestive

heart failure (CHF). These risk factors are the same as the HR3 population in the Company’s previous Phase 2 RSVHR trial where a one-week reduction in time to complete resolution of symptoms and a

reduction in hospitalization was observed. Patients will receive an oral dose of 800mg of zelicapavir or placebo once daily for 7 days and be evaluated for 28 days thereafter. The primary endpoint is the time to complete resolution of all 13 RSV

symptoms as measured by the RiiQ™ tool. A key secondary endpoint will evaluate hospitalization rate, with other secondary endpoints of additional clinical efficacy measures, antiviral

activity and safety of zelicapavir. The Phase 2b portion of the study will include a minimum of 200 patients and is designed to confirm the primary endpoint and treatment effect size in the targeted population with the optimized dosing duration and

will further support the Phase 3 portion of approximately 660 patients.

Pediatric Phase 2b Study

The Phase 2b, double-blind, placebo-controlled, multicenter trial in pediatric patients is designed to evaluate the efficacy and safety of zelicapavir in

hospitalized and non-hospitalized children with up to 72 hours of respiratory tract infection symptoms who test positive for RSV. Approximately 150 participants, 28 days to 36 months of age, will receive

5mg/kg (<12 months old) or 7.5 mg/kg (≥12 months old) of zelicapavir or placebo once daily for 7 days and be evaluated for 28 days thereafter. The primary endpoint is the time to complete resolution of clinical signs of RSV as measured by

the RESOLVE-P clinical scoring scale. Secondary endpoints will evaluate additional clinical efficacy measures, antiviral activity, and safety of zelicapavir. The trial is being conducted in Thailand in

collaboration with the Penta Foundation, and the AMS-PHPT Research Unit at Chiang Mai University, which has deep expertise and decades of experience in conducting infectious disease trials. In addition, its

network is comprised of clinical trial sites in geographies where the RSV season begins in the summer, making them an ideal partner to execute a timely start for this trial. Enanta plans to initiate this Phase 2b study in the third quarter of 2026

with topline data expected in 2027.

About Zelicapavir

Zelicapavir is being developed for the treatment of RSV infection and has been granted Fast Track designation by the U.S. Food and Drug Administration.

Zelicapavir inhibits the RSV N-protein with nanomolar activity against both RSV-A and RSV-B. This mechanism is differentiated

from RSV fusion inhibitors as targeting the N-protein inhibits viral replication versus viral entry and has a high barrier to resistance in vitro. In a Phase 2 trial of hospitalized and non-hospitalized pediatric RSV patients aged 28 days to 3 years old, zelicapavir demonstrated an antiviral effect and shortened time to complete resolution of RSV symptoms. In a Phase 2 trial of high-risk adults, a

clinically meaningful improvement in

time to complete resolution of all 13 RSV symptoms was observed for zelicapavir compared to placebo, with a benefit of 6.7 days for patients with congestive heart failure, chronic obstructive

pulmonary disease, or age 75 years or older, termed the HR3 population. Importantly, zelicapavir treatment resulted in a lower hospitalization rate, with an RSV-related hospitalization rate of 5% in placebo,

compared to 0% in patients who received zelicapavir. Throughout its clinical development program, zelicapavir has demonstrated a good safety profile and has been well-tolerated in more than 700 subjects to date.

About RSV

RSV is the most common cause of bronchiolitis

(inflammation of the small airways in the lung) and pneumonia in children under one year of age in the United States and a significant cause of respiratory illness in older adults and immunocompromised individuals.1,2 According to the Centers for Disease Control and Prevention, virtually all children in the United States get an RSV infection by the time they are two years old.3 RSV represents a significant health threat for adults older than 50 years of age, with up to 180,000 hospitalizations associated with RSV infections annually in the United States.2 Overall, in the United States, RSV accounts for up to 6.8 million outpatient visits and approximately 370,000 hospitalizations, with 24,000

deaths.4

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule

drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for RSV. The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune

response, with KIT, STAT6 and MRGPRX2 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment

regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and

MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie

contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.

Forward Looking Statements

This press release contains forward-looking statements, including statements with respect to the timeline and prospects for advancement of zelicapavir for the

treatment of RSV. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs

and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially

from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes,

Enanta’s clinical trials,

including its Phase 2b/3 trial, may fail to demonstrate sufficient safety and efficacy and, if that occurs, it may be unable to commercialize our product candidates on a timely basis or ever, the

impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV; the discovery and development risks of Enanta’s programs in virology and immunology; Enanta’s limited clinical

development experience; Enanta’s ability to partner its RSV or other programs; Enanta’s need to attract and retain senior management and key research and development personnel; Enanta’s need to obtain and maintain patent protection

for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s Form

10-K for the fiscal year-ended September 30, 2025, and any other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on

the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

References

Centers for Disease Control & Prevention – About RSV. Last accessed: June 2026.

Centers for Disease Control & Prevention – RSV In Adults. Last accessed: June 2026.

Centers for Disease Control & Prevention – RSV in Infants and Young Children. Last

accessed: June 2026.

CDC Preliminary Estimates of RSV Burden for 2024-2025; for period:

9/29/24-9/27/25. Last accessed June 2026.

Media and Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

EX-99.2

Filename: d159604dex992.htm · Sequence: 3

EX-99.2

Exhibit 99.2 Zelicapavir Update June 18, 2026 1

Forward Looking Statements Disclaimer This presentation contains

forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate.

Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,”

“anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,”

“may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and

other similar expressions that are predictions of or indicate future events and future trends, as well as other comparable terminology. These forward-looking statements include, but are not limited to, statements about overall trends, royalty

revenue trends, research and clinical development plans and prospects, liquidity and capital needs and other statements of expectations, beliefs, future plans and strategies, anticipated events or trends, and similar expressions. These

forward-looking statements are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions. These

forward-looking statements are not guarantees of future performance or results and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements

in this presentation may turn out to be inaccurate. Please refer to the risk factors described or referred to in “Risk Factors” in Enanta’s most recent Annual Report on Form 10-K, and other periodic reports filed with the

Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this presentation. These statements speak only as of the date of this presentation, and Enanta undertakes no

Enanta Overview Clinical-stage All compounds biotechnology company

discovered in dedicated to creating house, leveraging small molecule deep expertise in drugs for virology & medicinal chemistry, drug immunology indications 2 products approved with discovery & development Founded: 1995 STRONG CASH Public:

2013 POSITION CURED >1 million • Ongoing HCV royalties WHOLLY patients • $227M in cash at 4 Clinical-stage with OWNED March 31, 2026 2 Preclinical Hepatitis C PROGRAMS Virus © 2026 Enanta Pharmaceuticals, Inc. | 3

Enanta Pipeline DISEASE TARGET DISCOVERY PRECLINICAL PHASE 1 PHASE 2

PHASE 3 MARKET Virology: Hepatitis C Virus Protease Glecaprevir* Liver Zelicapavir High-Risk Adults N-Protein Respiratory Zelicapavir Pediatrics Syncytial Virus Virology: Respiratory L-Protein EDP-323 (challenge study) COVID-19 3CL Protease

EDP-235** SPRINT Chronic Spontaneous KIT EDP-978 Urticaria (CSU) Immunology: Type 2 Immune Atopic Dermatitis STAT6 EPS-3903 (AD) Diseases*** CSU/AD MRGPRX2 ® ® *Fixed-dose antiviral combination contains glecaprevir and AbbVie's NS5A

inhibitor, pibrentasvir. Marketed by AbbVie as MAVYRET (U.S.) and MAVIRET (ex-U.S.). **Continued development dependent on a future collaboration. ***Initial indications. Potential future indications include Asthma, Chronic Inducible Urticaria

Zelicapavir RSV Treatment Opportunity Summary • Enanta pioneering

development with zelicapavir, a potential first-in-disease RSV treatment First-in-Disease • First direct-acting therapeutic to demonstrate efficacy in adults at high risk for severe RSV Asset • Resolved symptoms ~7 days faster and

reduced hospitalization by 66% (Phase 2b) • Single Phase 2b/3 is a registrational path in high-risk adults Path to • Primary endpoint: Complete resolution of symptoms as measured by RiiQ Approval • Registrational development to

start 4Q 2026 with Phase 2b results expected 2027 – Additional expansion opportunities in pediatrics and other high risk adult populations • Despite preventatives, treatments needed as RSV is a major disease burden causing 1 Addresses

3.6m – 6.8m outpatient visits and 190k – 370k hospitalizations each year in the US Significant • Potential addressable population of >3 million patients in the US; with an RSV market Unmet Need 2 potential of up to ~$3.5B 1.

Respiratory Syncytial Virus: Disease Overview & Market Opportunity

Respiratory Syncytial Virus (RSV) Causes severe lung infections,

including bronchiolitis (infection of small airways in the lungs) and pneumonia. No safe and effective treatments are currently approved. 1 RSV Burden Estimates (2024 - 2025 U.S.) Significant Unmet Need for Antivirals • Adult vaccines have

sub-optimal adoption – Not recommended for all FDA-approved patient groups 2 3 – Vaccine adoption for elderly: ~35% (shingles ) to <50% (flu ) • Pediatric prophylaxis only provides passive immunity; up to 6.8M up to 370K up to

24K will shift first infection to next season – Antibody approach has a low barrier to resistance Populations at higher risk for severe illness • Pediatrics (infants and young children) • Breakthrough infections can occur despite

prophylaxis • High-risk adults (e.g.; >65 yrs, COPD, asthma, CHF) • Immunocompromised (e.g.; HIV, transplant) 1. CDC Preliminary Estimates of RSV Burden for 2024-2025; for period: 9/29/24-9/27/25 2. Terlizzi EP et al. NCHS Data Brief.

Physicians Report High Unmet Need for RSV, Driven by Lack of Treatment

Inpatient Unmet Need Outpatient Unmet Need Average Unmet Need 1 7 4.6 5.4 (Average rating on a 7-point scale where 1= no Low High unmet need and 7= extremely high unmet need) Unmet Need • Physicians desire an efficacious and indicated

treatment that curtails the progression of disease, decreases symptom severity, and minimizes duration of illness ® ® ‒ An ideal treatment would be given early, similar to PAXLOVID and TAMIFLU • ER and hospital physicians

particularly note desire for a treatment to decrease the length of stay, yet note minimal side effects is an important trade-off consideration • Currently available prevention lowers rating down from extremely high A lot of patients respond

with It would be nice if there was something I’m pretty satisfied with supportive care but There really is no anti-viral treatment for RSV. symptomatic management but there's not like Paxlovid or Tamiflu. Something that can its not a

treatment. We don't have antiviral It may require a visit to the ER or hospital, much else for those who don’t. We're kind be taken early and reduce risk of symptoms” medication for RSV – that is the greatest that's really

frustrating. ” of stuck and don’t have true satisfaction for “ “ “ “ unmet need.” RSV treatment.” – Hospital Internal Medicine / – Non-hospital Pediatrician – Non-hospital

Epidemiology: RSV Infections in the US Adult Population At Least 1.2

Million “HR3” Adults at High Risk for Severe RSV Most prevalent and highest risk for hospitalization ~1.2M addressable high-risk “HR3” adult RSV outpatients Additional ~0.6M CKD and IC patients 1600 HR3 Type 2 Diabetes

Chronic Kidney CHF Asthma 1400 COPD 700K Disease 1200 Most common & highest risk 1000 Immuno- compromised 460K CKD / IC 800 ≥75 Years Cancer 600 295K 270K 400 Pulmonary Fibrosis 200 Cystic Fibrosis 0 5.0% 6.0% 7.0% 8.0% 9.0% 10.0% 11.0%

12.0% Hospitalization Rate ≥75 COPD / CHF < 75 CKD < 75 IC < 75 More risk 2 3.25M total adult RSV outpatient & emergency department visits ; estimate of adults <75 yrs: 26% with COPD / 1 1 3 Data from ~67,000 outpatient RSV

infections that led to hospitalizations across the US CHF, 11% with CKD, 10% with IC adjusted for 35% co-morbidity overlap . Assumes impact of vaccines higher in age 75+ (10%) than COPD / CHF / CKD / IC < 75 (2%) CHF: Congestive Heart Failure;

COPD: Chronic Obstructive Pulmonary Disease; HR3: Patients with CHF, COPD, or age ≥75; IC: Immunocompromised CKD: Chronic Kidney Disease 1. Landi, SN et al. JAMA Netw Open. 2024 2. McLaughlin JM et al. Open Forum Infect Dis. 2022 3. Horn EK et

Epidemiology: RSV Infections in the US Pediatric Population ~1.5

Million Pediatrics at High Risk for Severe RSV 1 Despite RSV prophylaxis : Hospitalizations still occur in eligible population (0-7 mo) ~1.5M at-risk addressable pediatric RSV outpatients Passive protection may shift events to subsequent seasons

(8-60 mo) After Before prophylaxis prophylaxis (2024-25) (2018-20) ~70% protected 15.0 against LRTD due 1040K to prophylaxis 0 – 7 months 8.5 6.7 8 – 19 months 5.0 470K 590K At-risk 470K 2.5 19 - 60 months 1.5 0-11 months 12-23 months

24-36 months 2 Based on ~2.1m RSV outpatient and emergency department visits for ages 0 - 2 years before prophylaxis . US RSV-NET ~15,000 hospitalizations Assumptions: incidence age 24-36 mo 20% less than age 12-23 mo; 90% adoption of infant

mAb/maternal 3,4 vaccine with protection rates against RSV LRTD higher for mAb (~90%) than vaccine (~60%) LRTD: Lower Respiratory Tract Disease. RSV-NET: Respiratory Syncytial Virus Hospitalization Surveillance Network 1. Patton ME et al. MMWR.

Rapid At-Home RSV Tests Now Widely Available: Increase RSV Diagnosis

& Enable a Test-to-Treat Model Commercially available tests Combination Respiratory Viral Tests Now Available in major markets st • Self-test for RSV, FluA/B and COVID (1 FDA approval in 2025) • Quick results ~15 mins, appropriate

for pediatrics and adults Dual Benefit • Potential to accelerate patient enrollment in clinical trials • Increase in RSV diagnosis drives expanded commercial opportunity – 70% of US adults would test at home if they suspected

COVID-19 in post- 1 pandemic era – >2-times more likely to test if they have risk factors (increasing age, declining health status) 1. Fisher et al, JAMA Network Open, 2025 © 2026 Enanta Pharmaceuticals, Inc. | 11

Payers Recognize High RSV Disease Burden and Unmet Need, with Limited

Management for Antivirals Zelicapavir Viewed Positively by Payers, Limited Pricing Pressure on Antivirals Addressing RSV Disease Burden • Declining payer focus on respiratory viral • Payers recognize high disease burden and infections:

post-pandemic & availability of unmet need for high-risk RSV patients prophylactics • Surveyed payers believe that zelicapavir’s data package would justify pharmacy • Respiratory antivirals have limited coverage management as a

“rapid-access” category given strong public benefit & potential • Restrictions, if any, are dependent on downstream infection complications pricing Typically we manage respiratory therapies with quantity limits… Among

adults, the elderly and those with chronic Due to the acute nature of the treatment and needed to start in conditions such as COPD or congestive heart failure face a a time-sensitive manner, you're not seeing a lot of PAs in “ higher RSV

disease burden than healthier adults, with “ place. Paxlovid is covered preferred brand here with the more severe symptoms and a greater risk of hospitalization.” quantity limits. Tamiflu preferred generic with the quantity limit.

– PBM – IDN COPD: Chronic Obstructive Pulmonary Disorder; IDN: Integrated Delivery Network; PBM: Pharmacy Benefit Manager; PA: Prior Authorization Source: Trinity Primary US Market Research 2026 (n=15) © 2026 Enanta Pharmaceuticals,

Inc. | 12

Multi-Billion Dollar Global Market Opportunity for an RSV Antiviral 1

Up to 4M Addressable Patients with RSV in the United States ~4M Additional High-Risk Adults: 2 ~1.3M Multi-Billion $ Global Revenue Potential CKD, IC, T2DM, ONC ~$2.6B–3.5B HR3 Adults: • Additional High-Risk Adults ~1.2M CHF, COPD, Age

≥ 75 yrs • HR3 Adults ~$1.8B–2.4B • Pediatrics Pediatrics: ~1.5M Age < 3 yrs US Patients with RSV CHF: Congestive Heart Failure, CKD: Chronic Kidney Disease, COPD: Chronic Obstructive Pulmonary Disease, HR: High Risk; IC:

Immunocompromised, ONC: Oncology, T2DM: Type 2 Diabetes Mellitus 1. Addressable patients based on outpatient visits adjusted for: anticipated adoption & efficacy of RSV vaccination/prophylaxis; presence of selected comorbidities for adults.

Pediatrics: Lively JY et al. J Pediatr Infect Dis Soc 2019; Hsiao A et al. Pediatrics. 2025; ABRYSVO USPI Adults: Landi SN et al. JAMA Netw Open. 2024; Horn EK et al. Influenza Other Respir Viruses. 2025; McLaughlin JM et al. Open Forum Infect Dis.

2022 2. Peak sales forecast (2035); Based on primary market research and Enanta internal modeling that accounts for diagnosis, treatment and prescription fill rates. © 2026 Enanta Pharmaceuticals, Inc. | 13

Zelicapavir: Clinical Overview & Development Path 14

Zelicapavir (EDP-938): N-Protein Inhibitor for RSV • Only

N-inhibitor in clinical development for RSV RSV – Replication inhibitor: shuts down the production of new virions (vs. fusion inhibitors which block viral entry) • Granted Fast Track designation by the FDA • Strong preclinical

profile – Nanomolar potency against RSV-A and RSV-B – Antiviral potency across all clinical isolates tested – High barrier to resistance – Synergistic activity and no cross-resistance with other drug mechanisms (e.g.

L-inhibitors) • Favorable safety and efficacy profile in clinical studies – Challenge study showed statistically significant (p<0.001) reduction in viral load and clinical symptoms – High barrier to the development of clinical

RSV Development Goal: Treatment for Patients at High-Risk for Severe

RSV Infection Leading portfolio of RSV replication inhibitors with potential for first-in-disease (zelicapavir) and best-in-disease (EDP-323) treatments and ability for combination Age ≥65 years Zelicapavir High-Risk Adult Positive Phase 2b

Results Chronic heart or lung disease Phase 2b Study (e.g. COPD, CHF, asthma) Zelicapavir Pediatric Infants and young children Positive Phase 2 Results Phase 2 Study High-risk populations have reduced RSV immunity, resulting in a higher and longer

Zelicapavir Pediatric Program: First-in-Pediatric Phase 2 Study Design

Primary Objective Double-Blind Inclusion Criteria Treatment Phase • Hospitalized or outpatient pediatric Overall: Part 1: patients with RSV Antiviral activity MAD vs Placebo of zelicapavir • Symptom onset within 3 23 Day N=96 across all

patients days Follow-up Part 2: • Age: Part 1: Selected dose from Safety and PK ‒ ≥28 days – <6 months Part 1 vs Placebo Part 2: ‒ ≥6 months – ≤36 Antiviral activity months Day 1 Day 5 Day 28 First

Zelicapavir Pediatric Program: First-in-Pediatric Phase 2 Study Summary

• Well-tolerated, with favorable safety profile – No adverse events leading to treatment discontinuation or study withdrawal Primary Objectives of Study • Antiviral effect observed for the primary and secondary virology endpoints

in overall population üOverall: Antiviral activity of zelicapavir across all patients • Viral load decline of 1.4 log at the end of treatment in Part 2 • Viral load decline of 1.2 log at Day 5 observed in prespecified üPart 1:

Safety and PK subset of patients randomized within 3 days of symptom onset üPart 2: Antiviral activity • RSV Signs/Symptoms – ReSViNET: Reduced the time to complete symptom resolution by 1.6 days and 3.7 days – RESOLVE-P:

Trend toward greater sign/symptom reduction with zelicapavir in a small dataset Data support further clinical development of zelicapavir in pediatrics RESOLVE-P: RESpiratory ObservabLE Reported Outcome-Pediatric; Enanta’s proprietary ObsRO

Zelicapavir Pediatric Program: Phase 2b Study Design Primary Objective

Double-Blind Treatment Phase Randomized 1:1 Time to complete symptom Inclusion Criteria resolution as measured by RESOLVE-P Placebo (QD) • Pediatric outpatients 28 Day with RSV N=150 Follow-up • Symptom onset within 3 Secondary Objective

days Zelicapavir (QD)* • Age 28 days - 36 months Safety, virology, additional clinical efficacy measures Day 1 Day 7 Day 35 Study to start in 3Q 2026; Phase 2b topline data in 2027 *Doses are 5mg/kg for <12 months old; 7.5mg/kg for

≥12 months old QD: once-daily; RESOLVE-P: RESpiratory ObservabLE Reported Outcome-Pediatric; Enanta’s proprietary ObsRO © 2026 Enanta Pharmaceuticals, Inc. All rights reserved. © 2026 Enanta Pharmaceuticals, Inc. | 19 Trial

Design

Zelicapavir High-Risk Adult Program: Phase 2b Study Design Primary

Objective Double-Blind Inclusion Criteria Treatment Phase ‡ Time to resolution of RSV LRTD • Adult outpatients with Randomized 2:1 symptoms (RiiQ symptom scale) RSV Shortness of breath, wheezing, • Symptom onset within 3 Placebo

(QD) coughing, coughing up phlegm days 28 Day • At least one of N=186 the following:* Follow-up Secondary Objective † ‒ COPD 800mg (QD) PROs, MAVs, virology, antibiotic ‒ Congestive use, bronchodilator use, heart failure

(CHF) corticosteroid use, hospitalization, ‒ Asthma ICU, mechanical ventilation, all Day 1 Day 5 Day 33 ‒ Age ≥65 cause mortality, PK & safety • HR3 = ~80% of the population with CHF, COPD, or age >75 First

proof-of-concept Phase 2 high-risk adult outpatient study with positive clinical signal COPD: Chronic Obstructive Pulmonary Disease; LRTD: Lower respiratory Tract Disease; PROs: Patient Reported Outcomes; MAVs: Medically Attended Visits; ICU:

Intensive Care Unit; PK: Pharmacokinetics; QD: Once-daily † ‡ *Proportion of patients aged 65-74 years or those with asthma capped at 20% of the total population; Equivalent to 600mg suspension dosage form used in challenge study;

Zelicapavir Phase 2b High-Risk Adult Study Faster Time to Complete

Symptom Resolution by RiiQ Industry’s first proof-of-concept demonstrated in high-risk adult outpatients Efficacy Population HR3 Population* 7.2d 20 (34%) 6.7d 3.6d Placebo 18 (35%) (19%) Zelicapavir 16 2.2d (14%) 3.0d 14 (20%) 0.5d 12 (4%) 10

8 6 4 2 13.0 12.5 16.0 13.8 18.9 15.3 15.0 12.0 18.9 12.2 21.0 13.8 0 LRTD All RSV Total RiiQ LRTD All RSV Total RiiQ 4 Symptoms 13 Symptoms 29 Parameters 4 Symptoms 13 Symptoms 29 Parameters *HR3 Population = Patients with CHF, COPD, or age >75

Zelicapavir Phase 2b High-Risk Adult Study Faster Time to Symptom

Resolution by PGI-S • Statistically significant 2-day faster symptom resolution by PGI-S compared to placebo Efficacy Population (p=0.0446) H R3 Population (p=0.0465) Time Since First Dose (days) PGI-S: Patient Global Impression of Severity:

“In the past 24 hours, what was the severity of your overall RSV-related symptoms at their worst?” HR3 Population: Patients with CHF, COPD, or age >75 © 2026 Enanta Pharmaceuticals, Inc. | 22 Survival Probability of RSV Symptoms

Being Unresolved

Zelicapavir Phase 2b High-Risk Adult Study Hospitalization and Death

Endpoints • Lower hospitalization rate for patients treated with zelicapavir Placebo Zelicapavir All-cause hospitalizations 5.0% (3/60) 1.7% (2/115) RSV-associated hospitalizations 5.0% (3/60) 0% (0/115) (blinded investigator attribution)

Zelicapavir Phase 2b High-Risk Adult Study Conclusions •

Zelicapavir demonstrated compelling results on multiple clinically meaningful & potential registrational endpoints measuring different aspects of RSV disease ü Up to one week improvement in complete RiiQ symptom resolution ü

Statistically significant improvement in PGI-S ü Lower hospitalization rate • Robust antiviral effect • Well tolerated, with a favorable safety profile Data support advancing zelicapavir into registrational development RiiQ:

Zelicapavir Phase 2b/3 Study Elements Element Outcome Registrational

Path Single Phase 2b/3 Study TM Primary endpoint Time to complete resolution of all 13 RSV symptoms as measured RiiQ Study population Adult outpatients with CHF, COPD or 75 years or older (HR3) MITT of unvaccinated patients, vaccinated patients

(10%) would be Primary analysis set included in a separate supportive ITT analysis Sample size 860 Dosing duration 800 mg of zelicapavir per day for 7 days MITT: Modified Intent to Treat © 2026 Enanta Pharmaceuticals, Inc. | 25

Zelicapavir High-Risk Adult (HR3) Program: Phase 2b/3 Global

Registrational Study Design Primary Objective* Double-Blind Inclusion Criteria Treatment Phase Randomization 1:1 Time to complete resolution of • Adult outpatients with 13 RSV symptoms as RSV* measured by RiiQ • Symptom onset within 3

Placebo (QD) Ph2b/3 days 28 Day N= 200/ • At least one of Follow-up Secondary Objective the following: 660 800mg (QD) ‒ COPD Reduction in hospitalization rate due to RSV ‒ Congestive heart failure Other Secondary Objectives:

‒ Age ≥75 Additional clinical efficacy Day 1 Day 7 Day 35 measures, virology, safety Study to start in 4Q 2026; Phase 2b data in 2027 to confirm endpoints and sizing * Patients who have received an RSV vaccine are capped at 10%; Primary

endpoint is on MITT of unvaccinated patients (vaccinated patients included in a separate supportive ITT analysis) COPD: Chronic Obstructive Pulmonary Disease; PGI-S: Patient Global Impression of Severity; QD: Once-daily; RiiQ: Respiratory Infection

Zelicapavir RSV Treatment Opportunity Summary • Enanta pioneering

Enanta RSV Portfolio Enables Sustained Leadership Position Designed to

Address Broad Unmet Medical Needs First-in-Disease Best-in-Disease / Expansion Zelicapavir EDP-323 • Goal is to treat all high-risk patient populations (in/out-patients) – Pediatric patients (28 days – 3 years) – HR3 Adults:

≥75 years old, COPD, CHF – Chronic kidney disease, immunocompromised, diabetes, cancer • Possibility to develop as a preventative – Post-exposure prophylaxis for all populations – Pre-exposure prophylaxis for

immunocompromised • Potential to provide additional benefit in harder to treat patients (e.g. severely immunocompromised, etc) with a combination treatment COPD: Chronic Obstructive Pulmonary Disease; CHF: Congestive Heart Failure © 2026

Enanta Pharmaceuticals, Inc. | 28

www.enanta.com 29

GRAPHIC

Filename: g159604ex99_2p10g1.jpg · Sequence: 7

Binary file (294852 bytes)

Download g159604ex99_2p10g1.jpg

GRAPHIC

Filename: g159604ex99_2p11g1.jpg · Sequence: 8

Binary file (317566 bytes)

Download g159604ex99_2p11g1.jpg

GRAPHIC

Filename: g159604ex99_2p12g1.jpg · Sequence: 9

Binary file (432698 bytes)

Download g159604ex99_2p12g1.jpg

GRAPHIC

Filename: g159604ex99_2p13g1.jpg · Sequence: 10

Binary file (283138 bytes)

Download g159604ex99_2p13g1.jpg

GRAPHIC

Filename: g159604ex99_2p14g1.jpg · Sequence: 11

Binary file (116899 bytes)

Download g159604ex99_2p14g1.jpg

GRAPHIC

Filename: g159604ex99_2p15g1.jpg · Sequence: 12

Binary file (343215 bytes)

Download g159604ex99_2p15g1.jpg

GRAPHIC

Filename: g159604ex99_2p16g1.jpg · Sequence: 13

Binary file (296823 bytes)

Download g159604ex99_2p16g1.jpg

GRAPHIC

Filename: g159604ex99_2p17g1.jpg · Sequence: 14

Binary file (252328 bytes)

Download g159604ex99_2p17g1.jpg

GRAPHIC

Filename: g159604ex99_2p18g1.jpg · Sequence: 15

Binary file (352409 bytes)

Download g159604ex99_2p18g1.jpg

GRAPHIC

Filename: g159604ex99_2p19g1.jpg · Sequence: 16

Binary file (263046 bytes)

Download g159604ex99_2p19g1.jpg

GRAPHIC

Filename: g159604ex99_2p1g1.jpg · Sequence: 17

Binary file (122157 bytes)

Download g159604ex99_2p1g1.jpg

GRAPHIC

Filename: g159604ex99_2p20g1.jpg · Sequence: 18

Binary file (352304 bytes)

Download g159604ex99_2p20g1.jpg

GRAPHIC

Filename: g159604ex99_2p21g1.jpg · Sequence: 19

Binary file (280388 bytes)

Download g159604ex99_2p21g1.jpg

GRAPHIC

Filename: g159604ex99_2p22g1.jpg · Sequence: 20

Binary file (266667 bytes)

Download g159604ex99_2p22g1.jpg

GRAPHIC

Filename: g159604ex99_2p23g1.jpg · Sequence: 21

Binary file (192507 bytes)

Download g159604ex99_2p23g1.jpg

GRAPHIC

Filename: g159604ex99_2p24g1.jpg · Sequence: 22

Binary file (283492 bytes)

Download g159604ex99_2p24g1.jpg

GRAPHIC

Filename: g159604ex99_2p25g1.jpg · Sequence: 23

Binary file (226432 bytes)

Download g159604ex99_2p25g1.jpg

GRAPHIC

Filename: g159604ex99_2p26g1.jpg · Sequence: 24

Binary file (335975 bytes)

Download g159604ex99_2p26g1.jpg

GRAPHIC

Filename: g159604ex99_2p27g1.jpg · Sequence: 25

Binary file (357079 bytes)

Download g159604ex99_2p27g1.jpg

GRAPHIC

Filename: g159604ex99_2p28g1.jpg · Sequence: 26

Binary file (302480 bytes)

Download g159604ex99_2p28g1.jpg

GRAPHIC

Filename: g159604ex99_2p29g1.jpg · Sequence: 27

Binary file (107975 bytes)

Download g159604ex99_2p29g1.jpg

GRAPHIC

Filename: g159604ex99_2p2g1.jpg · Sequence: 28

Binary file (536656 bytes)

Download g159604ex99_2p2g1.jpg

GRAPHIC

Filename: g159604ex99_2p3g1.jpg · Sequence: 29

Binary file (333494 bytes)

Download g159604ex99_2p3g1.jpg

GRAPHIC

Filename: g159604ex99_2p4g1.jpg · Sequence: 30

Binary file (299272 bytes)

Download g159604ex99_2p4g1.jpg

GRAPHIC

Filename: g159604ex99_2p5g1.jpg · Sequence: 31

Binary file (353644 bytes)

Download g159604ex99_2p5g1.jpg

GRAPHIC

Filename: g159604ex99_2p6g1.jpg · Sequence: 32

Binary file (133084 bytes)

Download g159604ex99_2p6g1.jpg

GRAPHIC

Filename: g159604ex99_2p7g1.jpg · Sequence: 33

Binary file (343313 bytes)

Download g159604ex99_2p7g1.jpg

GRAPHIC

Filename: g159604ex99_2p8g1.jpg · Sequence: 34

Binary file (339294 bytes)

Download g159604ex99_2p8g1.jpg

GRAPHIC

Filename: g159604ex99_2p9g1.jpg · Sequence: 35

Binary file (304263 bytes)

Download g159604ex99_2p9g1.jpg

GRAPHIC

Filename: g159604g0609081059318.jpg · Sequence: 36

Binary file (8255 bytes)

Download g159604g0609081059318.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 38

v3.26.1

Document and Entity Information

Jun. 18, 2026

Cover [Abstract]

Entity Registrant Name

ENANTA PHARMACEUTICALS INC

Amendment Flag

false

Entity Central Index Key

0001177648

Document Type

8-K

Document Period End Date

Jun. 18, 2026

Entity Incorporation State Country Code

Entity File Number

001-35839

Entity Tax Identification Number

04-3205099

Entity Address, Address Line One

4 Kingsbury Avenue

Entity Address, City or Town

Watertown

Entity Address, State or Province

Entity Address, Postal Zip Code

02472

City Area Code

(617)

Local Phone Number

607-0800

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Security 12b Title

Common Stock, par value $0.01 per share

Trading Symbol

ENTA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration